Journal ArticleDOI
Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Sunder Mudaliar,Robert R. Henry,Arun J. Sanyal,Linda Morrow,Hanns-Ulrich Marschall,Mark Kipnes,Luciano Adorini,Cathi Sciacca,Paul Clopton,E. Castelloe,Paul Dillon,Mark Pruzanski,David Shapiro +12 more
Reads0
Chats0
TLDR
Administration of 25 or 50 mg OCA for 6 weeks was well tolerated, increased insulin sensitivity, and reduced markers of liver inflammation and fibrosis in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.About:
This article is published in Gastroenterology.The article was published on 2013-09-01. It has received 794 citations till now. The article focuses on the topics: Insulin resistance & Nonalcoholic fatty liver disease.read more
Citations
More filters
Journal ArticleDOI
Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies
Maria Pallayova,Shahrad Taheri +1 more
TL;DR: The diagnosis of primary NAFLD involves establishing the presence of hepatic steatosis or steatohepatitis by imaging or histology, along with establishing the non‐alcoholic nature of the disease process and excluding competing aetiologies for hepatic Steatosis.
Journal ArticleDOI
Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease.
TL;DR: Early evidence has suggested the potential of bile acid receptor agonists in NAFLD management, but their long-term safety and effectiveness need further clarification.
Journal ArticleDOI
Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Stefan Traussnigg,Christian Kienbacher,Emina Halilbasic,Christian Rechling,Lili Kazemi-Shirazi,Harald Hofer,P Munda,Michael Trauner +7 more
TL;DR: Recent progress in the management of patients with liver cirrhosis due to NASH is summarized.
Journal ArticleDOI
Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
Jonathan D. Roth,Sanne Skovgård Veidal,Louise K. D. Fensholdt,Kristoffer T.G. Rigbolt,Romeo Papazyan,Jens Nielsen,Michael Feigh,Niels Vrang,Mark Young,Jacob Jelsing,Luciano Adorini,Henrik H. Hansen +11 more
TL;DR: Findings provide preclinical proof-of-concept for combined FXR and PPAR-α/δ agonist-based therapies in NASH.
Journal ArticleDOI
Obeticholic acid for the treatment of nonalcoholic steatohepatitis.
Raj A Shah,Kris V. Kowdley +1 more
TL;DR: OCA likely improves fibrosis in NASH and therefore may have a beneficial effect in delaying or even preventing cirrhosis, and is likely to become an option for treatment, but the specific context within which it may be prescribed still needs to be clarified.
References
More filters
Journal ArticleDOI
Diagnosis and Classification of Diabetes Mellitus
TL;DR: The chronic hyperglycemia of diabetes is associated with long-term damage, dys-function, and failure of differentorgans, especially the eyes, kidneys, nerves, heart, and blood vessels.
Journal ArticleDOI
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
TL;DR: Methods for the quantification of beta-cell sensitivity to glucose (hyperglycemic clamp technique) and of tissue sensitivity to insulin (euglycemic insulin clamp technique] are described.
Journal ArticleDOI
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Takeshi Inagaki,Mihwa Choi,Antonio Moschetta,Li Peng,Carolyn L. Cummins,Jeffrey G. McDonald,Guizhen Luo,Stacey A. Jones,Bryan Goodwin,James A. Richardson,Robert D. Gerard,Joyce J. Repa,David J. Mangelsdorf,Steven A. Kliewer +13 more
TL;DR: It is demonstrated that fibroblast growth factor 15 signals from intestine to liver to repress the gene encoding cholesterol 7alpha-hydroxylase (CYP7A1), which catalyzes the first and rate-limiting step in the classical bile acid synthetic pathway.
Journal ArticleDOI
Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist.
Sama I. Sayin,Annika Wahlström,Jenny Felin,Sirkku Jäntti,Hanns-Ulrich Marschall,Krister Bamberg,Bo Angelin,Tuulia Hyötyläinen,Matej Orešič,Fredrik Bäckhed,Fredrik Bäckhed +10 more
TL;DR: It is suggested that the gut microbiota not only regulates secondary bile acids metabolism but also inhibits bile acid synthesis in the liver by alleviating FXR inhibition in the ileum.
Journal ArticleDOI
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
TL;DR: Results suggest that modulation of FXR activity and BA metabolism may open new attractive pharmacological approaches for the treatment of the metabolic syndrome and type 2 diabetes.
Related Papers (5)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more